The quality of antithrombotic therapy in patients with chronic atrial fibrillation: The AFib trial;Qualität der antithrombotischen therapie bei chronischem vorhofflimmern: AFib-studie

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 97, Issue 6, 2003, Pages 421-431

  Bücheler, Reinhild ^a   Meisner, Christoph ^c   Mörike, Klaus ^c   Fux, Richard ^c   Hauswald, Kirsten ^c   Lorenz, Gernot ^c   Kühlkamp, Volker ^b   Gleiter, Christoph H ^b  

^a MDK Baden Wurttemberg H R R H   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Universitats klinikum Tübingen ^*

Author keywords

Anticoagulation; Atrial fibrillation; Guidelines; Prospective cohort study; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING TENDENCY; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH CARE DELIVERY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL PRACTICE; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; QUALITY CONTROL; REVIEW; RISK MANAGEMENT; SINUS RHYTHM; STROKE; THROMBOEMBOLISM;

EID: 0041836269     PISSN: 14317621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Albers GW, Dalen JE, Laupacis A, Manning WJ, et al. (2001) Antithrombotic therapy in atrial fibrillation. Chest 119: 194S-206S
2. Arzneimittelkommission der Deutschen Ärzteschaft (AkdÄ) (1999) Arzneiverordnung in der Praxis. Empfehlungen zur Primär- und Sekundärprävention des ischämischen Insultes. Köln 1999, 1. Auflage
3. AWMF und ÄZQ (2001) Das Leitlinien Manual. München Urban und Fischer Verlag. Z ärztl Fortbild Qualsich 95: Suppl 1. http://www.uni-duesseldorf.de/WWW/AWMF/awmf-frp.htm
4. Bellelli G, Guerini F, Bianchetti A, Trabucchi M (2002) Anticoagulation treatment in disabled patients. Arch Intern Med 162: 107-108
5. Benavente O a, Hart R, Koudstaal P, Laupacis A, McBride R (2003) Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software
6. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R (2003) Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library, Issue 1 2003. Oxford: Update Software
7. Benjamin EJ, Wolf PA, D'Agostino RB, et al. (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98: 946-952
8. Bertomeu Martinez V, Morillas Blasco PJ, Gonzalez Juanatey JR, et al. (2002) Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study. Med Clin 118: 327-331
9. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM (2000) Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 85: 568-572
10. Butzlaff M, Floer B, Koneczny N et al. (2002) "www.evidence. de" - Netzbasierte Leitlinien im Praxistest. Beurteilung und Nutzung von evidenz-basierten und netzgestützten Leitlinien durch Allgemeinärzte und hausärztlich tätige Internisten. Z ärztl Fortbild Qualsich 96: 127-133
11. Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K (1999) Anticoagulation prophylaxis against stroke in atrial fibrillaion: affectiveness in actual practice. CMAJ 161: 493-497
12. Copland M, Walker ID, Tait RC (2001). Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 161: 2125-2128
13. Deutsches Institut für medizinische Dokumentation und Information (DIMDI) (Hrsg.) (1999) im Auftrage des Bundesministeriums für Gesundheit. ICD-10; Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheits-probleme, 10. Revision Band I; Systematisches Verzeichnis Version 1.3; Stand Juli 1999
14. Diener HC, et al. (2002) Primäre und Sekundäre Prävention in der zerebralen Ischämie. Leitlinien der Deutschen Gesellschaft für Neurologie. AWMF-Leitlinien-Register Nr. 030/075. Letzte Aktualisierung 20.04.2002. http://www.uni-dues-seldorf.de/WWW/AWMF/11/neur-075.htm (Stand 05.02.2003)
15. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, Nagpal S, Cox JL (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323: 1218-1222
16. Evans A, Kalra L (2001) Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 161: 1443-1447
17. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B (1999) Under-utilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 137: 307-312
18. Charité (2001). Medizinische Fakultät der Humboldt-Universität zu Berlin Campus Berlin-Buch am Max-Delbrü ck-Centrum für Molekulare Medizin. Vorhofflimmern, Leitlinienbasierte Therapieempfehlungen (04.07.2001). http://www.fvk-berlin.de/fvkweb/fvkevents/KardiologischerMittwoch/aFIB/aFIB2.pdf
19. Freeman AC, Sweeney K (2001) Why general practitioners do not implement evidence: qualitative study. BMJ 323: 1-5
20. Frost L, Johnsen SP, Pedersen L, Toft E, Husted S, Sorensen HT (2002) Atrial fibrillation or flutter and stroke: a Danish poplation-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med 252: 64-69
21. Frykman V, Beerman B, Ryden L, Rosenqvist M (2001). Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 22: 1954-1959
22. Fuster V, Rydén LE, Asinger RW, et al. (2001) ACC/AHA/ESC Guidelines for the Management of patients with atrial fibrillation: Executive Summary. Practice Guidelines. European Heart Journal 22, 1852-1923 http://www.escardio.org/scinfo/Tforceguidelines.htm
23. Gaughan GL, Dolan C, Wilk-Rivard E, Geary G, Libbey R, Gilman MA, Lanata H (2000) Improving management of atrial fibrillation and anticoagulation in a community hospital. Jt Comm J Qual Improv 26: 18-28
24. Giesler, U, Faber T, Grom A, Zehender M (2001) Antikoagulation bei Vorhofflimmern: Zwischen Anspruch und Realität im klinischen Alltag. Z Kardiol 90 (Suppl 2): 242
25. Go AS, Hylek EM, Phillips KA, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375
26. Hankey GJ (2001) Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. Med J Aust 174: 234-239
27. Hellemons BS, Langenberg M, Lodder J, et al. (1999) Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 319: 958-964
28. Hennersdorf MG, Perings C, Kelm M, Strauer BE (2001) Vorhofflimmern. Internist 42: 1631-1640
29. Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356: 1789-1794
30. Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY (2001) Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J 31: 329-336
31. Jacobs LG (2001) The sin of omission: a systematic review of anti-thrombotic therapy to prevent stroke in atrial fibrillation. J Am Geriatr Soc 49: 91-94
32. Jacobson AK, Makowski TM, Heywood JT, Linda L (1996) Anti-coagulation for atrial fibrillation - Translating research results into clinical practice. Anticoagulation Forum Newsletter 3 (1) http://www.acforum.org/newsletter/sept96/fibb.html
33. Jung J, Böhm M (2001) Vorhofflimmern-Therapie. Dtsch Med Wochenschr 126: 1472-1475
34. Kompetenznetz Schlaganfall, Heidelberg (Stand 04.02.2003) http://www.z2.stroke-trial.com/praevention/pp_arrhythmie.php
35. Lackie CL, Garbarino KA, Pruetz JA (2002) Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 36: 200-204
36. Laupacis A, Albers G, Dalen J, et al. (1998) Antithrombotic therapy in atrial fibrillation. In: American College of Chest Physicians (ACCP) (ed.): Proceedings of the American College of Chest Physicians 5th Consensus Conference on Anti-thrombotic Therapy. Chest; 114 (Suppl): 579S-589S
37. Majeed A, Moser K, Carroll K (2002) Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales 1994-1998: analysis of data from the general practice research database. Heart 86: 284-288
38. Ono A, Fujita T (2003) Stroke prevention in patients with atrial fibrillation. J Clin Neurosci 10: 71-72
39. Palareti G, Hirsh J, Legnani C, et al. (2000) Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 160: 470-478
40. Peterson GM, Boom K, Jackson SL, Vial JH (2002) Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 32: 15-23
41. Protheroe J, Fahey T, Montgomery AA, Peters TJ (2000) The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 320: 1380-1384
42. Rostock T (2000) Die Antikoagulation. In: Ambulante Therapie-gewohnheiten bei Vorhofflimmern in Berlin - eine deskriptive Untersuchung an Allgemeinmedizinern, Internisten und Kardiologen anhand eines Fragebogens und Vergleich der Ergebnisse mit nationalen und internationalen Therapieempfehlungen. Inauguraldissertation an der Freien Universität Berlin (15.12.2000): 48-54
43. Ruigomez A, Johansson S, Wallander MA, Rodriguez LA (2002) Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 55: 358-363
44. Sauermann W, Brüggenwerth G, Burkhardt M, Fritz T et al. (2001) Leitlinie Schlaganfall Sachsen. Stand 05.02.2003 http://www.imib.med.tu-dresden.de/schlag/LL_Stroke_Teil1.pdf
45. Scottish Intercollegiate Guidelines Network (SIGN) (04.02.2002) Anti-thrombotic therapy. A national clinical guideline. SIGN publication 36: 1-70, Stand 05.02.2003 http://www.guideline.gov/FRAME-SETS/guideline_fs.asp?guideline= 002133&sSearch_string=SIGN+and+atrial+fibrillation
46. Sulter G, Steen C, De Keyser J (1999) Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30: 1538-1541
47. The Atrial Fibrillation Follow-Up Investigaton of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control on patients with atrial fibrillation. N Engl J Med; 347: 1825-1833
48. Van Gelder IC, Hagens VE, Bosker HA for the Rate Control Versus Electrical Cardioversion For Persistent Atrial Fibrillation (RACE) study group (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834-1840
49. Van Steenkiste BC, Jacobs JE, Verheijen NM, et al. (2002) A Delphi technique as a method for selecting the content of an electronic patient record for asthma. Int J Med Inf 65: 7-16
50. Weiner M (2000) Targeting oral anticoagulation. Clin Pharmacol Ther 68: 4-5
51. Weisbord SD, Whittle J, Brooks RC (2001) Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med 16: 743-749
52. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 22: 983-988
53. Yermiahu T, Arbelle JE, Shwartz D, Levy Y, et al. (2001) Quality assessment of oral anticoagulant treatment in the Beer-Sheba district. Int J Qual Health Care 13: 209-213